Accelerating Patient Access: MHRA NICE Alignmen...

By João L. Carapinha

March 20, 2026

MHRA NICE alignment introduces a groundbreaking pathway launching on 1 April 2026, synchronizing the Medicines and Healthcare products Regulatory Agency (MHRA)'s licensing with the National Institute for Health and Care Excellence (NICE)'s value a...
TAVI Reimbursement Expansion for Low- and Intermediate-Risk Patients: A New E...
PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy
Europe Life Sciences Competitiveness: Addressing Decline and Unlocking Potential
Bridging Analyses: The Role of Cost Per Event Avoided in Evaluating GLP-1 Ago...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...